Long-Term Follow-Up After Thyroid Cancer: TSH Suppression, Thyroglobulin and Recurrence Management

Thyroid cancer, the most common type among differentiated thyroid cancers (papillary and follicular), is generally known for its excellent prognosis. The 10-year survival of papillary thyroid cancer exceeds 95%, while poorly differentiated forms such as anaplastic thyroid cancer follow a far more aggressive course. This wide spectrum shows that a single standard follow-up protocol will not be sufficient.

Recurrence risk never reaches zero. The late-recurrence characteristic of papillary thyroid cancer — reappearing even 10-20 years later in some cases — should be kept in mind. For this reason, ATA guidelines recommend periodic follow-up throughout life even for low-risk patients. Early-detected recurrence can be treated with re-surgery or RAI; late-detected recurrence may have progressed to distant metastasis.

In the post-thyroidectomy period, follow-up covers not only tumour surveillance but also fine-tuning of thyroid hormone replacement, monitoring of parathyroid function (risk of hypoparathyroidism) and assessment of the vocal cords (risk of recurrent laryngeal nerve damage). A multidisciplinary approach — endocrinology, ENT and radiology collaboration — determines the quality of long-term monitoring.

The ATA 2015 guideline's three-tier risk classification forms the basis of postoperative management decisions. Low risk: intrathyroid papillary microcarcinoma (<1 cm), BRAFV600E-negative, no vascular invasion, all macroscopic tumour resected, no cervical lymph node involvement or only ≤5 microscopic lymph node involvement (<0.2 cm). 10-year recurrence risk in this group is approximately 1-3%.

Intermediate risk is more broadly defined: moderately aggressive histology (tall cell, diffuse sclerosing variant), microscopic extrathyroid extension, vascular invasion, >5 lymph node metastases or extracapsular spread in a metastatic lymph node. 10-year risk in this group is 5-20%. High risk includes macroscopic extrathyroid extension, incomplete resection, distant metastasis or ≥3 cm large lymph node metastasis, and recurrence risk is determined as >20%.

Risk group directly determines RAI indication, TSH target and check-up frequency. A low-risk patient may never need RAI, while in a high-risk patient the threshold for fine-needle aspiration biopsy at all neck ultrasounds is kept low. This personalised approach prevents over- or under-treatment.

TSH is the primary growth factor that stimulates thyroid cancer cell growth. TSH is suppressed with levothyroxine dosing to prevent tumour proliferation. According to ATA 2015 recommendations: high-risk patients initially target TSH <0.1 mIU/L; intermediate-risk patients target 0.1-0.5 mIU/L; low-risk patients in remission target 0.5-2.0 mIU/L (i.e. slightly suppressed, at the lower normal limit).

However, long-term complications of TSH suppression therapy cannot be ignored. Suppressed TSH increases heart rate; prolonged exposure raises atrial fibrillation risk by 2-3%. It reduces bone mineral density, increasing osteoporosis risk — particularly pronounced in postmenopausal women. For this reason, as remission is achieved and recurrence risk decreases, the TSH target is gently raised.

Personalised risk models are now used: the patient's age, bone density, cardiac rhythm and comorbidities are incorporated into the TSH target. In patients over 65, with osteoporosis or cardiac arrhythmia, maintaining TSH in the normal range is preferred over aggressive suppression. Long-term suppression is not required for a low-risk patient with a remission certificate.

Thyroglobulin (Tg) is a protein produced only by thyroid tissue. After successful total thyroidectomy and RAI ablation, blood thyroglobulin levels are expected to approach zero (<0.2 ng/mL on stimulated measurement). If Tg begins to rise, this indicates residual thyroid tissue or recurrent/metastatic disease.

Anti-Tg antibodies (Anti-Tg Ab) can seriously affect measurement: in the presence of high Anti-Tg Ab, immunometric tests falsely show low Tg (false-negative). Therefore Tg must always be evaluated together with Anti-Tg Ab at every measurement. If Anti-Tg Ab decreases over time, it is a good prognostic sign; if it increases, it is an alarm signal for biochemical recurrence.

Stimulated Tg (with rhTSH or thyroid hormone withdrawal) is more sensitive than non-stimulated Tg. In low-risk remission patients, non-stimulated Tg can be checked annually; values below 1 ng/mL are considered safe. In intermediate/high-risk patients or with suspicious ultrasound findings, rhTSH (Thyrogen)-stimulated Tg measurement increases diagnostic sensitivity.

Neck ultrasound is the most sensitive imaging method for detecting lymph node recurrence and local recurrence. Routine ultrasound is performed at months 6 and 12 post-thyroidectomy for all patients; annual follow-up is transitioned to based on findings. Suspicious ultrasound criteria for recurrence: round morphology, absent hilum echo, cystic change, calcification or size exceeding 1 cm.

The central compartment (Level VI) and lateral neck lymph nodes are systematically evaluated. The lateral compartment is the most common recurrence site in the intermediate-to-high-risk group in the follow-up period. When ultrasound alone is insufficient, positron emission tomography/CT (PET/CT) or diagnostic whole-body scintigraphy (DxWBS) come into consideration as additional diagnostic tools.

Ultrasound-guided fine-needle aspiration biopsy (FNAB) is the confirmatory tool for suspicious lymph nodes. Tg measurement in aspirate fluid from a suspicious node (Tg-FNAB), especially in Anti-Tg Ab-positive patients, gives far more reliable information than serum Tg. The decision for re-surgery should be based on combined interpretation of radiological and clinical findings.

RAI ablation serves three different purposes: clearance of residual thyroid tissue (ablation), adjuvant treatment (in cases with distant metastasis or local recurrence) and diagnostic purposes (DxWBS). Over the past decade it has been shown that RAI in low-risk patients does not improve long-term survival. For this reason, ATA 2015 guidelines have markedly narrowed RAI indications.

Current RAI indications: large primary tumour (>4 cm), extrathyroid extension, distant metastasis or aggressive histology. RAI is no longer recommended in low-risk papillary microcarcinoma patients (<1 cm). In the intermediate-risk group RAI is debated and guided by multidisciplinary tumour board decision.

Pre-RAI preparation is important: either levothyroxine is withdrawn for 4-6 weeks (thyroid hormone withdrawal, for Tg rise) or 2 doses of rhTSH (Thyrogen, days 1 and 2) are administered. A low-iodine diet is followed for 2 weeks. Pregnancy is an absolute contraindication; breastfeeding mothers must wait at least 6 weeks.

ATA 2015 guidelines divide treatment response assessment into four categories: Excellent response — Tg undetectable or <0.2 ng/mL, no Anti-Tg Ab, no evidence of disease on imaging. Biochemical incomplete response — abnormal Tg or Anti-Tg Ab, no disease on imaging. Structural incomplete response — evidence of disease on imaging. Indeterminate response — nonspecific Tg variability or minor imaging findings.

In low-risk patients in the excellent response category, monitoring intervals can be extended: check-up every 6 months in the first 2 years, then annually, and after assessment at year 5, long-term follow-up every 1-2 years. TSH target in these patients is also raised to 0.5-2.0 mIU/L.

The biochemical incomplete response category is the most challenging group to manage. In these patients, Tg may not reach zero even after RAI; spontaneous remission may occur over time or progression to structural disease may occur. For this reason, frequent ultrasound and 6-monthly Tg follow-up is maintained. Re-surgery or RAI in structural recurrence is the most critical tumour board session decision.

Despite the excellent prognosis of thyroid cancer, patients can experience significant psychological morbidity. Anxiety created by the cancer diagnosis, fear reawakened by frequent check-ups and the long-lasting sense of 'am I still a cancer patient?' can persist for many years. Studies show that 30-40% of differentiated thyroid cancer patients report significant anxiety symptoms.

Levothyroxine treatment and calcium supplementation (if hypoparathyroidism is present) should be optimised to improve daily life. Fatigue, weight changes, hair loss and concentration problems are linked to TSH levels and can largely be resolved with dose adjustment. In our clinic's co-led endocrinology follow-up sessions, these side effects are systematically queried.

Remote follow-up options are available for international patients. Annual ultrasound and Tg assessment, along with a comprehensive report, can be shared with the oncologist in the patient's home country. For global tele-consultation options see our tele-tip page.